TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03737916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cc 5% Dextrose solution
Description: Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5 cc salin
Description: Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
Study: NCT03790241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insertion of a catheter
Description: Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
Study: NCT00264381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin sodium injection
Description: Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
Study: NCT01830309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Description: Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Description: Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition
Study: NCT02909517

Intervention type: OTHER
Intervention: cSLO imaging

Intervention type: OTHER
Intervention: cSLO imaging

Intervention type: OTHER
Intervention: cSLO imaging

Intervention type: OTHER
Intervention: cSLO imaging

Intervention type: OTHER
Intervention: cSLO imaging
Study: NCT03462602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NGT group
Description: After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-NGT group
Description: After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
Study: NCT00564343

Intervention type: OTHER
Intervention: water based training program to improve balance
Description: The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
Study: NCT00623558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
Study: NCT03442192

Intervention type: OTHER
Group type: OTHER
Intervention: PrEP Care Anywhere Services
Description: PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing
Study: NCT03129061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection.
Study: NCT03990116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral
Description: Posture lateral kangaroo care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone
Description: Posture prone kangaroo care
Study: NCT01953172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AMP-886
Description: AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
Study: NCT03578263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
Study: NCT02290327

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of 0.9% normal saline
Study: NCT02427828

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visensia Respiration Rate Estimation Service (VRES)
Description: Medical device product to provide respiration rate from PPG signal
Study: NCT03578263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergometrine
Description: intramuscular ergometrine 0.2 mg.
Study: NCT03757715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 mL of 1.3% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2 mg dexamethasone
Study: NCT01550965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study: NCT06429085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rex robotic assisted balance exercises
Description: Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
Study: NCT01649427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Hexal
Description: Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg.
Study: NCT02739568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant (BF2.649)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04251273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This is Quitting
Description: Text message-based intervention for quit vaping support.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment only Control
Description: Assessment only
Study: NCT01798680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
Study: NCT01986023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS- Short Messaging Service
Study: NCT01601561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular human insulin injection
Description: Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose.
Study: NCT01798680

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
Study: NCT00725504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Description: Intravenous lidocaine administered up to 5 µg/ml.
Study: NCT00160173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel
Study: NCT01918358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)
Study: NCT04426513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy with magnetotherapy
Description: Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy with magnetotherapy
Description: Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy with magnetotherapy
Description: Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
Study: NCT00087672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: 10 mg orally (2 capsules) daily
Study: NCT00160173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03278080

Intervention type: OTHER
Group type: OTHER
Intervention: Car-following test
Description: Driving with simulator program for DCV measurement
Study: NCT00879372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tianeptine
Description: tianeptine 12,5mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 12.5 mg TID
Study: NCT03712761

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enriched Protein®
Description: This product contains high quality bovine milk proteins enriched with additional leucine.
Study: NCT03568123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC polyethylene bearing
Description: Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CR polyethylene bearing
Description: Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old.
Study: NCT01830465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (VELCADE)
Description: 1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
Study: NCT02998866

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophageal Temperature-Guided Ablation
Description: Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
Study: NCT03713411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urethral catheter placement
Description: urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
Study: NCT00732797

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-treatment booklet
Description: A booklet outlining vestibular rehabilitation exercises
Study: NCT04691115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules
Study: NCT04691115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1476
Description: AM1476 Capsules
Study: NCT00732797

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote telephone support
Description: Up to an hour's remote support from an expert vestibular therapist
Study: NCT04150939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core biospy
Study: NCT04150939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation
Study: NCT03278080

Intervention type: OTHER
Group type: OTHER
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study: NCT04417062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
Study: NCT04691115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT04150939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: Receive standard of care immunotherapy
Study: NCT02080637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Once daily oral dosing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01720836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + PolyICLC
Description: The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + PolyICLC
Description: The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + PolyICLC
Description: The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
Study: NCT00398879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 50 mg/d qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
Study: NCT02054377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai chi
Description: Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD.
Study: NCT00398879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks